Sanofi and Regeneron’s immunology blockbuster Dupixent had been on a mini streak as king of the pharma airwaves but was knocked off its perch in June by AbbVie’s competing drug Rinvoq. That’s ...
The long-running “Du More” motif for Sanofi and Regeneron’s immunology blockbuster Dupixent is looking to make a splash with its first new commercial of 2023. In the 60-second spot, “It's Possible: ...
Dupixent had the most impressions and largest impressions share of voice (SOV) among Rx and over-the-counter (OTC) brands in March, according to data released by iSpot.tv Monday evening. This is a ...
19don MSN
Regeneron targets $7B in U.S. manufacturing investment as R&D and commercial launches accelerate
Q3 2025 Management View CEO Leonard Schleifer reported "double-digit net sales growth for 3 of our leading products," highlighting a 26% increase in Dupixent, 24% for Libtayo at constant exchange ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback